Abstract: An apparatus for cup loading and unloading and a thromboelastography machine are provided. The apparatus for cup loading and unloading includes a base, a shaft, a movable cover, and a cup holder. The shaft is rotatably connected to the base about an axis of the shaft and has an end configured to engage with an inner cup. The movable cover is disposed around the shaft and slidably connected to the base along the axis of the shaft. The movable cover is provided with an elastic member therein. The cup holder is slidably connected to the base along the axis of the shaft and disposed below the base and the shaft. The cup holder has a cavity configured to engage with an outer cup, and the cavity has an open directed upward.

Abstract: An apparatus for cup loading and unloading and a thromboelastography machine are provided. The apparatus for cup loading and unloading includes a base, a shaft, a movable cover, and a cup holder. The shaft is rotatably connected to the base about an axis of the shaft and has an end configured to engage with an inner cup. The movable cover is disposed around the shaft and slidably connected to the base along the axis of the shaft. The movable cover is provided with an elastic member therein. The cup holder is slidably connected to the base along the axis of the shaft and disposed below the base and the shaft. The cup holder has a cavity configured to engage with an outer cup, and the cavity has an open directed upward.

Abstract: The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.

Abstract: An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.

Abstract: An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.

Abstract: The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.